Notes to editor
This press release accompanies both a presentation and an ESC press conference at ESC Congress 2025.
It does not necessarily reflect the opinion of the European Society of Cardiology.
ESC Press Office
Tel: +33 6 61 40 18 84
Email: press@escardio.org
Follow European Society of Cardiology News on LinkedIn
Funding: The trial was sponsored by Alnylam Pharmaceuticals and Roche.
Disclosures: Doctor Pagidipati reports research support from Alnylam, Amgen, Bayer, Boehringer Ingelheim, Eli Lilly, Novartis, Novo Nordisk, Merck. Consultation/Advisory Panels for Alnylam, Amgen, Bayer, Boehringer Ingelheim, Corcept, Corsera, Eli Lilly, Esperion, AstraZeneca, Merck, New Amsterdam, Novartis and Novo Nordisk. Executive Committee member for phase IV trials sponsored by Novo Nordisk and Novartis. Executive Committee member for phase II/III registration trials sponsored by Alnylam, AZ, Amgen andNew Amsterdam. DSMB for trials sponsored by J+J and Novartis.
References and notes:
1‘KARDIA-3: Zilebesiran as add-on therapy in adults with hypertension and established cardiovascular disease or at high cardiovascular risk’ presented during HOT LINE 4 on 30 August 2025 at 16:30 to 16:40 in Madrid (Main Auditorium).
2GBD 2021 Risk Factors Collaborators. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403:2162−2203.
3Burnier M, Egan BM. Adherence in hypertension. Circ Res. 2019;124:1124−1140.
4Desai AS, Karns AD, Badariene J, et al. Add-on treatment with zilebesiran for inadequately controlled hypertension: The KARDIA-2 randomized clinical trial. JAMA. 2025;334:46−55.
About ESC Congress 2025
It is the world’s largest gathering of cardiovascular professionals, disseminating ground-breaking science both onsite in Madrid and online – from 29 August to 1 September 2025. Explore the scientific programme. More information is available from the ESC Press Office at press@escardio.org.
About the European Society of Cardiology
The ESC brings together healthcare professionals from more than 150 countries, working to advance cardiovascular medicine and help people to live longer, healthier lives.